Welcome to our dedicated page for Cullinan Oncology SEC filings (Ticker: CGEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cullinan Therapeutics, Inc. (Nasdaq: CGEM) SEC filings page on Stock Titan provides access to the company’s public disclosures filed with the U.S. Securities and Exchange Commission. These documents include Current Reports on Form 8-K, which Cullinan uses to report material events such as clinical data updates, financial results, regulatory milestones, and significant corporate actions related to its biopharmaceutical business.
For a clinical-stage company like Cullinan, SEC filings are a primary source of detail on the development of its T cell engager and targeted therapy programs. Recent 8-K filings describe updated Phase 1 data for CLN-049, an FLT3xCD3 bispecific T cell engager in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, including response rates, safety findings, and the impact of FDA Fast Track designation. Other filings summarize financial results, cash and investment levels, and expectations for cash runway under the company’s operating plan.
Filings may also reference Cullinan’s work in autoimmune diseases with CLN-978, a CD19xCD3 bispecific T cell engager, and its collaboration with Taiho Oncology and Taiho Pharmaceutical on zipalertinib (CLN-081/TAS6417), an EGFR inhibitor for non-small cell lung cancer. These reports can include information on clinical timelines, regulatory interactions, and program prioritization decisions, such as the discontinuation of certain assets or the termination of license agreements.
On Stock Titan, investors can review Cullinan’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, helping to interpret complex clinical and regulatory language. Users can monitor new 8-K submissions in real time and place them in context with the company’s broader pipeline and news flow, supporting deeper analysis of CGEM’s risk profile, development progress, and strategic direction.
Lynx1 Capital Management LP and affiliated reporting person Weston Nichols disclosed purchases of Cullinan Therapeutics, Inc. (CGEM) common stock across three days. On
Cullinan Therapeutics, Inc. (CGEM) Form 3 shows that Lynx1 Capital Management LP and individual Weston Nichols reported an initial beneficial ownership event dated
Cullinan Therapeutics received a Schedule 13G amendment showing Lynx1 Capital Management LP and Weston Nichols together beneficially own 8,549,084 shares of common stock, representing
Cullinan Therapeutics disclosed that Lynx1 Capital Management LP and Weston Nichols collectively report beneficial ownership of 4,400,842 shares, representing 7.5% of the outstanding common stock based on 59,014,667 shares outstanding as of April 30, 2025. The holdings are reported as shared voting and dispositive power, with no sole voting or dispositive power indicated.
This Schedule 13G filing identifies the investment manager (Lynx1) and Mr. Nichols as reporting persons and states the shares are held by the Lynx1 Master Fund. The filing includes a certification that the position was not acquired to change or influence control of the company.
Cullinan Therapeutics director Doyle Mittie received a stock option award to purchase 79,456 shares of the company’s common stock. The grant has an exercise price of $7.03 per share and was transacted on 08/07/2025. The option vests in three equal installments: one-third on each of the first, second and third anniversaries of the grant date, conditioned on the Reporting Persons continued service as a director.
The option is held directly, the reported number of derivative securities beneficially owned after the transaction is 79,456, and the option has an indicated expiration date of 08/07/2035.
Cullinan Therapeutics director Andrew R. Allen was granted a stock option on 08/07/2025 to purchase 79,456 shares of the company's common stock at an exercise price of $7.03 per share. The option vests in three equal installments—one-third on each of the first, second and third anniversaries of the grant date—subject to continued service as a director, and the instrument expires on 08/07/2035.
The reported transaction shows the reporting person beneficially owning 79,456 shares following the award. The filing documents a routine director equity award that creates the right to acquire shares over time under standard vesting conditions.
Cullinan Therapeutics (CGEM) Form 3: Andrew R. Allen filed an initial Section 16 statement on behalf of himself as a director of Cullinan Therapeutics reporting the event date 08/07/2025. The filing states that no securities are beneficially owned by the reporting person. The form was signed by an attorney-in-fact, Jacquelyn Sumer, on 08/08/2025. No derivative or non-derivative holdings are listed.
Doyle Mittie, listed with an address at Cullinan Therapeutics, Inc., One Main Street, Cambridge, MA, filed an initial Form 3 disclosing his relationship to the issuer as a Director. The filing, reporting the event date 08/07/2025, states explicitly that no securities are beneficially owned by the reporting person. The signature block shows the form was signed by Jacquelyn Sumer, Attorney-in-Fact on 08/08/2025. This is an initial ownership disclosure required under Section 16 and indicates the reporting person holds no reportable equity in Cullinan Therapeutics, Inc. (CGEM) as of the reported date.
FAQ
What is the current stock price of Cullinan Oncology (CGEM)?
What is the market cap of Cullinan Oncology (CGEM)?
